Pfizer, a publicly owned company headquartered in the US, was founded in 1849. The company employs approximately 100,900 people and specializes in pharmaceutical manufacturing.
Pfizer shares closed down 1.04% at $26.58 on March 14, despite recent positive drug trial results and an ongoing cost-cutting plan, as broader market weakness impacted healthcare stocks. Earlier that day, researchers reported in The New England Journal of Medicine that a trial directly comparing Eliquis and Xarelto found Eliquis carries a lower risk of dangerous bleeding in patients with deep blood clots. This follows China's approval of Pfizer's GLP-1 obesity therapy, Xianweiying (ecnoglutide), on March 13, granting the company commercialization rights in mainland China for the therapy obtained from Sciwind Biosciences. Also on March 13, a federal judge rejected attempts by Pfizer, Teva, and other major drugmakers to disqualify a former prosecutor representing private health insurers in a U.S. generic drug price-fixing case, after he previously led similar antitrust lawsuits for U.S. states.
Subscribe for full access to Pfizer's products in full detail
Subscribe for full access to Pfizer's revenue in full detail
Subscribe for full access to Pfizer's products in full detail 
